Evolocumab in High-Risk Primary Prevention: Is Earlier Intervention Warranted in Diabetes?

Overview of ASCVD: residual risk remains high in selected primary prevention patients

Atherosclerotic cardiovascular disease (ASCVD) remains one of the leading causes of death worldwide. Over the past decades, statins have become the cornerstone of lipid management because of their well-established ability to reduce low-density lipoprotein cholesterol (LDL-C) and improve cardiovascular outcomes. More recently, non-statin therapies have expanded treatment options, particularly for patients who require further LDL-C reduction beyond what statins alone can achieve.

However, the strongest outcome data for intensive lipid lowering have traditionally come from secondary prevention settings, where patients already have established ASCVD. This leaves an important clinical question unanswered: should more aggressive LDL-C lowering be considered earlier, before overt atherosclerotic disease becomes clinically apparent?

This question is especially relevant in patients with diabetes. Even in the absence of documented ASCVD, many individuals with longstanding diabetes, insulin dependence, or microvascular complications carry a markedly elevated cardiovascular risk. Evolocumab - a PCSK9 inhibitor has gained attention as a potential strategy for selected patients in high-risk primary prevention.

Study findings: deeper LDL-C reduction and fewer first cardiovascular events

A prespecified subgroup analysis of the randomized VESALIUS-CV trial evaluated 3,655 patients with diabetes who were considered at high cardiovascular risk but had no known significant atherosclerotic disease. Participants received Evolocumab every two weeks or placebo, in addition to standard lipid-lowering therapy such as statins and/or ezetimibe.

The primary efficacy endpoints included a 3-point major adverse cardiovascular event (3P-MACE) composite of coronary heart disease death, myocardial infarction, or ischemic stroke, as well as a 4-point MACE endpoint that also included ischemia-driven coronary revascularization.

Key study findings

• Baseline LDL-C: median 121 mg/dL in the lipid analysis population
• At week 48: Evolocumab reduced mean LDL-C by approximately 51%
• Median LDL-C at week 48: 52 mg/dL with Evolocumab vs 111 mg/dL with placebo
• Median LDL-C at week 96: 44 mg/dL with Evolocumab vs 105 mg/dL with placebo
• Evolocumab also reduced other atherogenic lipid markers, including non–HDL-C and Apolipoprotein B

Cardiovascular outcomes

• 3P-MACE: 5.0% with Evolocumab vs 7.1% with placebo
  • Relative risk reduction: 31%
  • HR 0.69; p=0.009
• 4P-MACE: 7.6% with Evolocumab vs 10.5% with placebo
  • Relative risk reduction: 31%
  • HR 0.69; p=0.001

Landmark analysis

• Beyond year 1, Evolocumab was associated with:
  • 41% reduction in 3P-MACE
  • 39% reduction in 4P-MACE

Secondary outcomes

• 34% reduction in the composite of myocardial infarction, ischemic stroke, or coronary revascularization
• 31% reduction in coronary heart disease death, myocardial infarction, or coronary revascularization
• 32% reduction in cardiovascular death, myocardial infarction, or ischemic stroke
• Favorable trends were also observed for cardiovascular death and all-cause mortality, although these were considered exploratory

Conclusion: a signal toward earlier intensive LDL-C lowering

This analysis suggests that in high-risk patients with diabetes but no established ASCVD, adding Evolocumab to standard lipid-lowering therapy may not only produce deep and sustained LDL-C reduction, but also reduce the risk of a first cardiovascular event.

The clinical implication is not necessarily that all patients with diabetes should receive PCSK9 inhibition. Rather, the findings support a more individualized approach in which selected primary prevention patients with particularly high risk may benefit from earlier intensification of lipid-lowering therapy. This reflects a broader shift in cardiovascular prevention: moving from reacting to clinical events toward preventing the first event before irreversible vascular disease becomes evident.

If confirmed by further evidence and incorporated into future treatment pathways, this strategy could reshape how clinicians think about ASCVD prevention in diabetes—placing greater emphasis on earlier risk recognition, deeper LDL-C lowering, and more proactive protection against cardiovascular events.

Source

1. MedicalXpress - access March 2026
2. doi: 10.1001/jama.2026.3277